<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pregabalin - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/depressants/">Depressants</a> ‚Üí <span>Pregabalin</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Pregabalin</h1>
        <h2 class="chemical-name">(S)-3-(aminomethyl)-5-methylhexanoic acid</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Pregabalin" 
                data-category="Depressants" 
                data-chemical="(S)-3-(aminomethyl)-5-methylhexanoic acid">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Lyrica</span> ‚Ä¢ <span>Pregaba</span> ‚Ä¢ <span>Lecaent</span> ‚Ä¢ <span>Nervalin</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Budz</span> ‚Ä¢ <span>Pregabs</span> ‚Ä¢ <span>Lyrical</span> ‚Ä¢ <span>Anxiety Pills</span>
            </div>
            <div class="name-category">
              <h4>Clinical/Medical</h4>
              <span>Gabapentinoid</span> ‚Ä¢ <span>Anticonvulsant</span> ‚Ä¢ <span>Anxiolytic</span>
            </div>
            <div class="name-category">
              <h4>Chemical Abbreviations</h4>
              <span>PGB</span> ‚Ä¢ <span>CI-1008</span> ‚Ä¢ <span>(S)-Pregabalin</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status schedule-5">Schedule V</span>
          <span class="duration long">4-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/pregabalin.jpg" alt="Pregabalin capsules and tablets" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇàH‚ÇÅ‚ÇáNO‚ÇÇ</p>
            <p>MW: 159.23 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Pregabalin</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder</li>
            <li><strong>Texture:</strong> Fine crystalline solid</li>
            <li><strong>Odor:</strong> Odorless</li>
            <li><strong>Taste:</strong> Bitter</li>
            <li><strong>Solubility:</strong> Freely soluble in water and methanol</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Commercial Forms</h4>
          <ul>
            <li><strong>Capsules:</strong> 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg</li>
            <li><strong>Oral solution:</strong> 20mg/mL (473mL bottles)</li>
            <li><strong>Extended-release:</strong> 82.5mg, 165mg, 330mg tablets</li>
            <li><strong>Generic forms:</strong> Various manufacturers, same dosage options</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Authenticity Concerns</h4>
          <p><strong>Prescription diversion:</strong> Legitimate pharmaceutical products diverted from medical use</p>
          <p><strong>Counterfeit risk:</strong> Low due to prescription status, but fake pills exist online</p>
          <p><strong>Cross-contamination:</strong> Risk when obtained from non-medical sources</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">50-75mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">75-150mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">150-300mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">300-600mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">600mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Medical Dosing Guidelines</h4>
        <ul>
          <li><strong>Anxiety (GAD):</strong> Start 150mg/day divided, up to 600mg/day</li>
          <li><strong>Neuropathic pain:</strong> Start 150mg/day, up to 600mg/day</li>
          <li><strong>Fibromyalgia:</strong> Start 150mg/day, up to 450mg/day</li>
          <li><strong>Epilepsy:</strong> Start 150mg/day, up to 600mg/day adjunctive</li>
          <li><strong>Renal impairment:</strong> Dose reduction required</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Critical Warning:</strong> Pregabalin has significant abuse potential. Physical dependence can develop within weeks of regular use. Never stop abruptly after extended use.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-1:00</span>
          <span class="effect">Onset - relaxation, anxiety relief</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+1:00-3:00</span>
          <span class="effect">Peak - euphoria, sociability, pain relief</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+3:00-6:00</span>
          <span class="effect">Plateau - sustained anxiolysis, mood elevation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-12:00</span>
          <span class="effect">Comedown - gradual return to baseline</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Positive Effects</h4>
          <ul>
            <li>Profound anxiety relief</li>
            <li>Euphoria and wellbeing</li>
            <li>Enhanced sociability and confidence</li>
            <li>Pain relief (neuropathic)</li>
            <li>Improved sleep quality</li>
            <li>Mood elevation and disinhibition</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects</h4>
          <ul>
            <li>Sedation and drowsiness</li>
            <li>Dizziness and ataxia</li>
            <li>Cognitive impairment</li>
            <li>Weight gain (chronic use)</li>
            <li>Peripheral edema</li>
            <li>Severe withdrawal syndrome</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Pregabalin is a selective, high-affinity ligand for the Œ±2Œ¥ subunit of voltage-gated calcium channels (VGCCs) in the CNS. By binding to this subunit, it reduces calcium influx at nerve terminals, thereby decreasing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. This mechanism differs fundamentally from GABA receptor modulation, despite structural similarity to GABA.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±2Œ¥-1 VGCC subunit</strong></span>
            <span class="affinity">Very high affinity (Kd: 9 nM)</span>
            <span class="function">Primary therapeutic target - reduces neurotransmitter release</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±2Œ¥-2 VGCC subunit</strong></span>
            <span class="affinity">High affinity (Kd: 30 nM)</span>
            <span class="function">Secondary effects on synaptic transmission</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>L-type amino acid transporter</strong></span>
            <span class="affinity">Active substrate</span>
            <span class="function">CNS uptake mechanism, blood-brain barrier transport</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA receptors</strong></span>
            <span class="affinity">No direct binding</span>
            <span class="function">Indirect modulation through reduced glutamate release</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> No hepatic metabolism - excreted unchanged by kidneys</p>
          <p><strong>Active Metabolites:</strong> None - parent compound is active drug</p>
          <p><strong>Half-life:</strong> 6.3 hours (normal renal function)</p>
          <p><strong>Bioavailability:</strong> ‚â•90% oral administration (dose-independent)</p>
          <p><strong>Peak plasma:</strong> 1.5 hours after oral dose</p>
          <p><strong>Renal clearance:</strong> Directly proportional to creatinine clearance</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <div class="neurotoxicity-info">
          <p><strong>No hepatic metabolism:</strong> Minimal drug-drug interactions through CYP system</p>
          <p><strong>Linear pharmacokinetics:</strong> Predictable dose-response relationship</p>
          <p><strong>CNS selectivity:</strong> High brain penetration with selective calcium channel binding</p>
          <p><strong>Dependence potential:</strong> Physical dependence develops faster than other gabapentinoids</p>
        </div>

        <h4>Neurochemical Effects</h4>
        <ul>
          <li><strong>Glutamate reduction:</strong> Decreased excitatory neurotransmission in pain/anxiety circuits</li>
          <li><strong>Substance P inhibition:</strong> Reduced nociceptive signaling in spinal cord</li>
          <li><strong>Norepinephrine modulation:</strong> Anxiolytic effects through reduced NE release</li>
          <li><strong>Sleep architecture:</strong> Increased slow-wave sleep, reduced REM latency</li>
          <li><strong>Reward system:</strong> Indirect dopaminergic effects contributing to abuse potential</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Physical dependence:</strong> Can develop within 2-4 weeks of regular use</li>
            <li><strong>Severe withdrawal:</strong> Life-threatening seizures possible</li>
            <li><strong>Respiratory depression:</strong> Dangerous with opioids or alcohol</li>
            <li><strong>Suicidal ideation:</strong> Increased risk in first weeks of treatment</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Precautions</h4>
          <ul>
            <li>Never combine with opioids or alcohol</li>
            <li>Avoid driving or operating machinery</li>
            <li>Monitor for mood changes or suicidal thoughts</li>
            <li>Taper slowly when discontinuing</li>
            <li>Use minimum effective dose</li>
            <li>Regular medical monitoring for dependence</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Absolute:</strong> Known hypersensitivity to pregabalin. <strong>Relative:</strong> Severe renal impairment, history of substance abuse, respiratory compromise, elderly patients with cognitive impairment.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>Opioids:</strong> Severe respiratory depression, increased overdose risk</li>
            <li><strong>Alcohol:</strong> Enhanced CNS depression, respiratory depression</li>
            <li><strong>Benzodiazepines:</strong> Synergistic sedation, respiratory depression</li>
            <li><strong>Barbiturates:</strong> Profound CNS depression</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Other gabapentinoids:</strong> Additive effects, increased side effects</li>
            <li><strong>Antihistamines:</strong> Enhanced sedation</li>
            <li><strong>Muscle relaxants:</strong> Increased CNS depression</li>
            <li><strong>Sleep aids:</strong> Profound sedation risk</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>ACE inhibitors:</strong> Increased risk of angioedema</li>
            <li><strong>Lorazepam:</strong> Reduced lorazepam clearance</li>
            <li><strong>CNS depressants:</strong> Monitor for excessive sedation</li>
            <li><strong>Diabetes medications:</strong> Monitor blood glucose</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule V</strong> - Prescription required. Lower abuse potential than Schedule IV substances but controlled due to dependence risk.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Prescription Only Medicine (POM)</strong> - Since 2019, reclassified as Class C controlled substance due to abuse concerns.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá™üá∫ European Union</h4>
            <p><strong>Prescription Medicine</strong> - Varying controls across member states, increasing recognition of abuse potential.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 4</strong> - Prescription Only Medicine with increasing regulatory scrutiny due to misuse reports.</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Status</h4>
          <p>Approved for generalized anxiety disorder, neuropathic pain, fibromyalgia, and adjunctive epilepsy treatment. Increasing regulatory concerns about off-label use and abuse potential.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1990s</span>
          <p>Developed by Pfizer as follow-up to gabapentin with improved pharmacokinetics</p>
        </div>
        <div class="history-event">
          <span class="year">2004</span>
          <p>FDA approval for neuropathic pain associated with diabetic peripheral neuropathy</p>
        </div>
        <div class="history-event">
          <span class="year">2005</span>
          <p>Approved for postherpetic neuralgia and adjunctive epilepsy treatment</p>
        </div>
        <div class="history-event">
          <span class="year">2007</span>
          <p>Fibromyalgia approval makes it first FDA-approved fibromyalgia treatment</p>
        </div>
        <div class="history-event">
          <span class="year">2009</span>
          <p>Generalized anxiety disorder approval expands psychiatric use</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Emergence of recreational use and abuse reports, street value increases</p>
        </div>
        <div class="history-event">
          <span class="year">2019</span>
          <p>UK reclassifies as Class C controlled substance due to abuse concerns</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>Pregabalin represents a shift in anxiety treatment but also highlighted the ongoing tension between therapeutic benefit and abuse potential. Its euphoric effects made it popular in recreational drug communities, leading to increased regulatory scrutiny and concerns about prescription drug abuse.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Abuse Liability Studies</h4>
          <p>Ongoing research into pregabalin's abuse potential, particularly in combination with opioids and among patients with substance use disorders.</p>
        </div>
        
        <div class="research-item">
          <h4>Withdrawal Management</h4>
          <p>Investigation of optimal tapering schedules and adjunctive treatments for pregabalin discontinuation syndrome.</p>
        </div>
        
        <div class="research-item">
          <h4>Novel Indications</h4>
          <p>Research into pregabalin for alcohol withdrawal, restless leg syndrome, and treatment-resistant depression.</p>
        </div>
        
        <div class="research-item">
          <h4>Biomarker Development</h4>
          <p>Studies identifying genetic and clinical predictors of therapeutic response and abuse risk.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.drugs.com/lyrica.html">Drugs.com</a> - Comprehensive prescribing information</li>
          <li><a href="https://www.rxlist.com/lyrica-drug.htm">RxList</a> - Detailed pharmacology and side effects</li>
          <li><a href="https://www.webmd.com/drugs/2/drug-93965/lyrica-oral/details">WebMD</a> - Patient information and interactions</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Recovery</h4>
        <ul>
          <li><a href="https://www.benzowithdrawal.com/">Benzo Withdrawal</a> - Gabapentinoid withdrawal support</li>
          <li><a href="https://www.reddit.com/r/gabapentin/">/r/gabapentin</a> - User experiences and support</li>
          <li><a href="https://www.survivingantidepressants.org/">Surviving Antidepressants</a> - Withdrawal and tapering resources</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Research & Education</h4>
        <ul>
          <li><a href="https://pubmed.ncbi.nlm.nih.gov/">PubMed</a> - Scientific literature on pregabalin</li>
          <li><a href="https://www.erowid.org/pharms/pregabalin/">Erowid</a> - Experience reports and information</li>
          <li><a href="https://psychonautwiki.org/wiki/Pregabalin">PsychonautWiki</a> - Pharmacology and effects</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>